GMPs expressing an MLL fusion oncogene could produce two types of progeny: differentiated ones despite the oncogene expression, or malignant ones that could eventually develop into lethal acute myeloid leukemia (AML) in vivo. This evidence concerns the gene KMT2A and acute myeloid leukemia.